In line with the decision to engage stakeholders in the pharmaceutical sector, Gaviscon, a non-prescription pharmaceutical brand from the stables of Reckitt Benckiser, a multinational consumer goods company, has partnered a major stakeholder - the Society for Gastroenterology and Hepatology in Nigeria (SOGHIN), to host the seventh scientific conference and annual general meeting of the association in Enugu.
The partnership is in line with Gaviscon's determination to explore new ways of treating Gastro-Oesophageal Reflux Disease (GERD).
Tagged 'Challenges of Gastroenterology Practice in Nigeria', the event featured insightful presentations by a reputable international faculty.
Preceding the SOGHIN conference, Gaviscon hosted members of the golden faculty, a think tank put forward by the brand. The event brought together eminent medical professionals in the fields of gastroenterology, hepatology, family medicine, pharmacy and other allied specialties.
Themed: 'Gastro-Oesophageal Reflux Disease, Where Are We?', the session was facilitated by a notable gastroenterologist, Dr. Asif Nqvi, Consultant Gastroenterologist and Director of Medical Education at Princess Diana of Wales Hospital, United Kingdom. Dr. Sumaila Adamu.
Highlighting how the brand works, Marketing Manager, Healthcare Reckitt Benckiser West Africa, Qaiser Rashid, said when a person has heartburn or reflux disease, Gaviscon goes into the stomach and forms a raft on top which prevents the acid pepsin and bile from coming on top.
Speaking on the effectiveness of the brand in treating GERD, Dr. Asif Naqvi, stated that Gaviscon is a very old time effective product such that it has become a home remedy. His words: "Over the years we have understood exactly how Gaviscon works and why it's so much effective than the so called other simple antacids. So far this product has been treated as if it was one of the antacids the fact is that Gaviscon is not an antacid but a separate product which has got a definite mechanism of action which is very effective".
In the same vein, Adamu emphasized the effectiveness of the brand in treating patients with GERD. He said, "Gaviscon is a very good innovation in the management of gastro-oesophageal reflux disease because it is an alginate which tends to give a lot of protection to the acid irritation oesophagus. It is a very important molecule to the gastroenterologists".